{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T04:49:20Z","timestamp":1782103760210,"version":"3.54.5"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To develop and internally validate a clinical prediction model for identifying asymptomatic type 2 diabetes (T2DM) patients at risk of incident heart failure (HF) or progression of subclinical cardiac dysfunction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This single-center retrospective study included 326 asymptomatic T2DM patients with preserved LVEF, all with \u22653 echocardiographic assessments over 24 months. The primary outcome was a composite of incident clinical HF (classified as HFpEF or HFrEF based on symptoms, hospitalization, natriuretic peptides, and follow-up echo) and imaging-defined progression of subclinical dysfunction. Candidate predictors (clinical variables, GLS, LASr, E\/e\u2032, LAVI, LVMI, NT-proBNP, galectin-3) were pre-specified. Missing data were handled by multiple imputation. A risk score was derived using multivariable Cox regression with Fine-Gray competing risk analysis, and optimism was assessed via bootstrap, 5-fold cross-validation, and internal split-sample validation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Over 24 months, LV GLS modestly declined (17.4\u00a0\u00b1\u00a02.0% to 16.9\u00a0\u00b1\u00a02.1%), while LASr deteriorated more (38.5\u00a0\u00b1\u00a07.2% to 34.0\u00a0\u00b1\u00a06.5%). Independent predictors of the composite outcome were LASr \u226424% (HR 3.58), NT-proBNP \u2265120 pg\/mL (HR 2.48), galectin-3 \u226515 ng\/mL (HR 1.79), age \u226570 years, diabetes duration \u226512 years, BMI \u226530 kg\/m\u00b2, and UACR \u226560 mg\/g; SGLT2i\/GLP-1 RA use was associated with lower observed risk. During follow-up, 40 patients reached the composite outcome (18 clinical HF: 14 HFpEF, 4 HFrEF; 22 imaging-only progression). The scoring system stratified patients into low- (\u22643 points), intermediate- (4\u20136), and high-risk (\u22657) groups, with 24-month cumulative incidences of 4.2%, 11.7%, and 27.5% (Gray\u2019s test P&amp;lt;0.001). The full model had a C-statistic of 0.835 (bootstrap-corrected 0.828) and good calibration (Brier score 0.068). Adding LASr and galectin-3 improved discrimination (\u0394C=0.058 and 0.012, both P&amp;lt;0.05).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Integrating LASr, galectin-3, and clinical risk factors may help identify asymptomatic T2DM patients at higher risk of incident HF or subclinical progression. This internally validated model may support preliminary risk stratification for suspected early diabetic cardiomyopathy, but external validation and clinical utility assessment are needed before routine use.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1882872","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T04:32:47Z","timestamp":1782102767000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Predicting heart failure in asymptomatic diabetes: derivation and internal validation of a clinical prediction model for early detection of diabetic cardiomyopathy"],"prefix":"10.3389","volume":"17","author":[{"given":"Yu","family":"Cao","sequence":"first","affiliation":[{"name":"Department of Chinese Materia Medica and Natural Medicines, School of Pharmacy, The Air Force Medical University","place":["Xi\u2019an, Shaanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenwen","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Chinese Materia Medica and Natural Medicines, School of Pharmacy, The Air Force Medical University","place":["Xi\u2019an, Shaanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunyuan","family":"Tian","sequence":"additional","affiliation":[{"name":"Department of Chinese Materia Medica and Natural Medicines, School of Pharmacy, The Air Force Medical University","place":["Xi\u2019an, Shaanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Li","sequence":"additional","affiliation":[{"name":"The College of Pharmacy, Shaanxi University of Chinese Medicine","place":["Xianyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Xu","sequence":"additional","affiliation":[{"name":"The College of Life Pharmacy, Northwest University","place":["Xi\u2019an, Shaanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haifeng","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Chinese Materia Medica and Natural Medicines, School of Pharmacy, The Air Force Medical University","place":["Xi\u2019an, Shaanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(25)00299-2","article-title":"11th edition of the IDF Diabetes Atlas: global, regional, and national diabetes prevalence estimates for 2024 and projections for 2050","volume":"14","author":"Genitsaridi","year":"2026","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2023.111054","article-title":"Diabetes and risk of heart failure in people with and without cardiovascular disease: systematic review and meta-analysis","volume":"207","author":"Panchal","year":"2024","journal-title":"Diabetes Res Clin Pract"},{"key":"B3","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/s12916-024-03401-3","article-title":"Prevalence of diabetic cardiomyopathy in patients with type 2 diabetes in a large academic medical center","volume":"22","author":"Swiatkiewicz","year":"2024","journal-title":"BMC Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-022-10238-6","article-title":"Diabetes leading to heart failure and heart failure leading to diabetes: epidemiological and clinical evidence","volume":"28","author":"Palazzuoli","year":"2023","journal-title":"Heart Fail Rev"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.2337\/dbi23-0019","article-title":"Redefining diabetic cardiomyopathy: perturbations in substrate metabolism at the heart of its pathology","volume":"73","author":"Heather","year":"2024","journal-title":"Diabetes"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.2174\/011573403X331870241025094307","article-title":"Diabetic cardiomyopathy: an update on emerging pathological mechanisms","volume":"21","author":"Kakkar","year":"2025","journal-title":"Curr Cardiol Rev"},{"key":"B7","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s12933-024-02273-4","article-title":"Therapeutic strategies targeting mechanisms of macrophages in diabetic heart disease","volume":"23","author":"Zhang","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1401961","article-title":"Diabetes cardiomyopathy: targeted regulation of mitochondrial dysfunction and therapeutic potential of plant secondary metabolites","volume":"15","author":"Pan","year":"2024","journal-title":"Front Pharmacol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2024.1375400","article-title":"Molecular mechanisms of metabolic dysregulation in diabetic cardiomyopathy","volume":"11","author":"Zeng","year":"2024","journal-title":"Front Cardiovasc Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s12933-025-02707-7","article-title":"Metabolic rewiring and inter-organ crosstalk in diabetic HFpEF","volume":"24","author":"Luo","year":"2025","journal-title":"Cardiovasc Diabetol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1405031","article-title":"The role of multimodality imaging in diabetic cardiomyopathy: a brief review","volume":"15","author":"Adel","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.3271","article-title":"Echocardiographic predictors of cardiovascular outcome in heart failure with preserved ejection fraction","volume":"26","author":"Wang","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12081690","article-title":"Beyond blood sugar: how left atrium strain predicts cardiac outcomes in type 2 diabetes","volume":"12","author":"Benchea","year":"2024","journal-title":"Biomedicines"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3390\/medicina60030395","article-title":"Effects of liraglutide, empagliflozin and their combination on left atrial strain and arterial function","volume":"60","author":"Katogiannis","year":"2024","journal-title":"Med (Kaunas)"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcha.2023.101329","article-title":"Impact of sodium glucose co-transporter-2 inhibitors on left atrial functions in patients with type-2 diabetes and heart failure with mildly reduced ejection fraction","volume":"50","author":"El-Saied","year":"2023","journal-title":"Int J Cardiol Heart Vasc"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2313917","article-title":"Semaglutide in patients with obesity-related heart failure and type 2 diabetes","volume":"390","author":"Kosiborod","year":"2024","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1451100","article-title":"Update on clinical and experimental management of diabetic cardiomyopathy: addressing current and future therapy","volume":"15","author":"Galis","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B18","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1186\/s13098-025-01913-3","article-title":"Deep phenotyping of a modified diabetic cardiomyopathy mouse model which reflects clinical disease progression","volume":"17","author":"Karuna","year":"2025","journal-title":"Diabetol Metab Syndr"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1714219","article-title":"Investigating the biomarkers of diabetic-cardiomyopathy with the high mobility group box-1 as a potential anti-inflammatory therapeutic target: systematic review and meta-analysis","volume":"16","author":"Ranasinghe","year":"2026","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jproteome.5c00937","article-title":"Identifying diabetic cardiomyopathy biomarkers via proteomic and glycation modification analysis using DIA and PRM","volume":"25","author":"Lin","year":"2026","journal-title":"J Proteome Res"},{"key":"B21","doi-asserted-by":"publisher","first-page":"18718","DOI":"10.1038\/s41598-025-98753-y","article-title":"Identification of metabolic pathways and serum biomarkers in diabetic cardiomyopathy using untargeted metabolomics","volume":"15","author":"Li","year":"2025","journal-title":"Sci Rep"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.70081","article-title":"Established and emerging roles of epigenetic regulation in diabetic cardiomyopathy","volume":"41","author":"Russell-Hallinan","year":"2025","journal-title":"Diabetes Metab Res Rev"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.echo.2014.01.001","article-title":"Longitudinal myocardial strain alteration is associated with left ventricular remodeling in asymptomatic patients with type 2 diabetes mellitus","volume":"27","author":"Ernande","year":"2014","journal-title":"J Am Soc Echocardiogr"},{"key":"B24","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s12933-016-0454-x","article-title":"Cholesterol remnants and triglycerides are associated with decreased myocardial function in patients with type 2 diabetes","volume":"15","author":"J\u00f8rgensen","year":"2016","journal-title":"Cardiovasc Diabetol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s13098-024-01285-0","article-title":"Early signs of myocardial systolic dysfunction in patients with type 2 diabetes are strongly associated with myocardial microvascular dysfunction independent of myocardial fibrosis: a prospective cohort study","volume":"16","author":"Bojer","year":"2024","journal-title":"Diabetol Metab Syndr"},{"key":"B26","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s12933-023-01804-9","article-title":"The independent association of myocardial extracellular volume and myocardial blood flow with cardiac diastolic function in patients with type 2 diabetes: a prospective cross-sectional cohort study","volume":"22","author":"Bojer","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1093\/ehjci\/jey164","article-title":"Predictive value of echocardiography in type 2 diabetes","volume":"20","author":"J\u00f8rgensen","year":"2019","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"B28","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s12933-020-01063-y","article-title":"Impact of diabetes mellitus on left ventricular longitudinal function of patients with non-ischemic dilated cardiomyopathy","volume":"19","author":"Tanaka","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9092681","article-title":"Depressed cardiac mechanical energetic efficiency: a contributor to cardiovascular risk in common metabolic diseases-from mechanisms to clinical applications","volume":"9","author":"Juszczyk","year":"2020","journal-title":"J Clin Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8071044","article-title":"Depressed myocardial energetic efficiency increases risk of incident heart failure: the strong heart study","volume":"8","author":"Losi","year":"2019","journal-title":"J Clin Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.23736\/S2724-5683.23.06478-5","article-title":"Effects of dapagliflozin on cardiac function and short-term prognosis of patients with both acute myocardial infarction and type 2 diabetes mellitus","volume":"72","author":"Zhou","year":"2024","journal-title":"Minerva Cardiol Angiol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.119.044183","article-title":"Effect of dapagliflozin on atrial fibrillation in patients with type 2 diabetes mellitus: insights from the DECLARE-TIMI 58 trial","volume":"141","author":"Zelniker","year":"2020","journal-title":"Circulation"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12041586","article-title":"Improvement of left ventricular global longitudinal strain after 6-month therapy with GLP-1RAs semaglutide and dulaglutide in type 2 diabetes mellitus: a pilot study","volume":"12","author":"Basile","year":"2023","journal-title":"J Clin Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.33963\/v.phj.100613","article-title":"The impact of using SGLT-2 inhibitor on left ventricular longitudinal strain and NT-proBNP levels during six-month follow-up in diabetic patients with and without coronary artery disease with preserved ejection fraction","volume":"82","author":"Biter","year":"2024","journal-title":"Kardiol Pol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2024.08.021","article-title":"Effect of semaglutide on cardiac structure and function in patients with obesity-related heart failure","volume":"84","author":"Solomon","year":"2024","journal-title":"J Am Coll Cardiol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1882872\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T04:32:57Z","timestamp":1782102777000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1882872\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,22]]},"references-count":35,"alternative-id":["10.3389\/fendo.2026.1882872"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1882872","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,22]]},"article-number":"1882872"}}